The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature by Jamshidi, N & Cohen, M
Thank you for downloading this document from the RMIT 
Research Repository. 
The RMIT Research Repository is an open access database showcasing 
the research outputs of RMIT University researchers. 
RMIT Research Repository: http://researchbank.rmit.edu.au/ 
PLEASE DO NOT REMOVE THIS PAGE
Citation: 
See this record in the RMIT Research Repository at:
Version:
Copyright Statement:
©
Link to Published Version:
Review Article
The Clinical Efficacy and Safety of Tulsi in Humans:
A Systematic Review of the Literature
Negar Jamshidi andMarc M. Cohen
School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia
Correspondence should be addressed to Marc M. Cohen; marc.cohen@rmit.edu.au
Received 21 December 2016; Revised 20 February 2017; Accepted 22 February 2017; Published 16 March 2017
Academic Editor: Daniela Rigano
Copyright © 2017 Negar Jamshidi and Marc M. Cohen. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Tulsi, also known as holy basil, is indigenous to the Indian continent and highly revered for its medicinal uses within the
Ayurvedic and Siddha medical systems. Many in vitro, animal and human studies attest to tulsi having multiple therapeutic actions
including adaptogenic, antimicrobial, anti-inflammatory, cardioprotective, and immunomodulatory effects, yet to date there are
no systematic reviews of human research on tulsi’s clinical efficacy and safety. We conducted a comprehensive literature review
of human studies that reported on a clinical outcome after ingestion of tulsi. We searched for studies published in books, theses,
conference proceedings, and electronic databases including Cochrane Library, Google Scholar, Embase, Medline, PubMed, Science
Direct, and IndianMedical databases. A total of 24 studies were identified that reported therapeutic effects on metabolic disorders,
cardiovascular disease, immunity, and neurocognition. All studies reported favourable clinical outcomes with no studies reporting
any significant adverse events.The reviewed studies reinforce traditional uses and suggest tulsi is an effective treatment for lifestyle-
related chronic diseases including diabetes, metabolic syndrome, and psychological stress. Further studies are required to explore
mechanisms of action, clarify the dosage and dose form, and determine the populationsmost likely to benefit from tulsi’s therapeutic
effects.
1. Introduction
Tulsi in Hindi or Tulasi in Sanskrit (holy basil in English)
is a highly revered culinary and medicinal aromatic herb
from the family Lamiaceae that is indigenous to the Indian
subcontinent and beenusedwithinAyurvedicmedicinemore
than 3000 years. In the Ayurveda system tulsi is often referred
to as an “Elixir of Life” for its healing powers and has been
known to treat many different common health conditions. In
the IndianMateriaMedica tulsi leaf extracts are described for
treatment of bronchitis, rheumatism, and pyrexia [1]. Other
reported therapeutic uses include treatment of epilepsy,
asthma or dyspnea, hiccups, cough, skin and haematological
diseases, parasitic infections, neuralgia, headache, wounds,
and inflammation [2] and oral conditions [3].The juice of the
leaves has been applied as a drop for earache [4], while the tea
infusion has been used for treatment of gastric and hepatic
disorders [5].The roots and stemswere also traditionally used
to treat mosquito and snake bites and for malaria [5].
Three types of tulsi are commonly described. Ocimum
tenuiflorum (or Ocimum sanctum L.) includes 2 botanically
and phytochemically distinct cultivars that include Rama or
Sri tulsi (green leaves) and Krishna or Shyama tulsi (purplish
leaves) [6, 7], while Ocimum gratissimum is a third type
of tulsi known as Vana or wild/forest tulsi (dark green
leaves) [8, 9]. The different tulsi types exhibit vast diversity
in morphology and phytochemical composition including
secondary metabolites, yet they can be distinguished from
other Ocimum species by the colour of their yellow pollen,
high levels of eugenol [10], and smaller chromosome number
[11]. Despite being distinct species with Ocimum tenuiflorum
having six times less DNA than Ocimum gratissimum [11],
they are traditionally used in the same way to treat similar
ailments [5]. For consistency, this review uses the term tulsi
to refer to bothOcimum tenuiflorum orOcimum gratissimum.
Tulsi has been the subject of numerous scientific studies
and its pharmacological and wide range of therapeutic appli-
cations are the subject ofmore than one hundred publications
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during the last decade alone. Numerous in vitro and animal
studies attest to tulsi leaf having potent pharmacological
actions that include adaptogenic [12–14], metabolic [15–
17], immunomodulatory [18–20], anticancer [21–23], anti-
inflammatory [24, 25], antioxidant [26, 27], hepatoprotective
[28, 29], radioprotective [30, 31], antimicrobial [32–35],
and antidiabetic effects [36–38] that have been extensively
reviewed previously [39–45].
Preclinical studies have demonstrated that tulsi increases
swimming survival times inmice andprevents stress-induced
ulcers in rats [46] with antistress effects comparable to
antidepressant drugs [47]. Similarly, recent studies report leaf
extracts from ethanolic and aqueous tulsi protects rats from
stress-induced cardiovascular changes [48, 49]. Studies in
animalmodels have further shown that the leaf extract of tulsi
possesses anticonvulsant and anxiolytic activities [50, 51].
Several animal studies conducted over the past fifty years
report that ingestion of tulsi leaves improves both glucose and
lipid profiles in normal and diabetic-induced animal models
[36, 38, 52–58]. Tulsi aqueous leaf extract intramammary
infusion has also showed promising effect on improving the
immune response in bovine models [59].
In addition to the extensive literature documenting in
vitro and animal research, studies on the use of tulsi as part of
a polyherbal formulation in humans has been systematically
reviewed [60]. To date, however, there are no systematic
reviews on the clinical efficacy and safety of tulsi as a single
herbal intervention in humans. The objective of this review
was therefore to summarize and critically appraise human
clinical trials of tulsi in order to assess the current evidence
on tulsi’s clinical efficacy and safety.
2. Methods and Materials
2.1. Search Strategies. Relevant clinical studies were identified
through searching PubMed, Google Scholar, ScienceDirect,
Medline, Embase, Cochrane Library, and Indian Medical
databases. The terms in the title or abstract (MeSH and
free search terms) alone or in combination searched were
“Tulsi”, “Tulasi”, “Holy Basil”, “ocimum sanctum”, “Ocimum
tenuiflorum”, “Ocimum gratissimum”, “ocimum”, “Albahaca
Morada” or combined with “clinical trial”, “clinical”, or
“human”.
2.2. Inclusion Criteria. Studies were included if they reported
on a human intervention study that involved ingestion of
any form of tulsi or holy basil (Ocimum sanctum or Ocimum
tenuiflorum orOcimum gratissimum) and at least one clinical
outcome.
2.3. Exclusion Criteria. Studies were excluded if they were
reviews, were nonclinical studies, did not involve human
subjects, did not report a biological outcome, only involved
topical application or only used tulsi at part of a polyherbal
formulation, and did not report on the use of tulsi as a single
herbal intervention.
2.4. Study Selection. All the titles and abstracts were screened
on the basis of the predetermined inclusion and exclusion
criteria described above. The full text of each article was
reviewed to assess suitability of the study with duplications
removed. The search included clinical studies written in the
English language and articles from inception until November
2016 in the above-mentioned electronic databases. The refer-
ences of selected articles were manually searched to identify
further relevant studies and, where appropriate, study authors
were contacted to request further information.
2.5. Quality Assessment. In order to evaluate the quality
of design and implementation of trials, information was
collected on the study design, randomization, blinding, and
description of participant dropouts and the Jadad scale was
used to assess methodological quality [84].
2.6. Data Extraction. Eligible studies were reviewed with
the following data extracted and tabulated: (1) first author
name and year of publication; (2) design of the study; (3)
Jadad score; (4) study participants (intervention and control
groups); (5) extraction method; (6) duration of intervention;
(7) tulsi dose and dose form (8) comparator; (9) outcome
measure(s) including both primary and secondary, and (10)
any adverse event(s).
3. Results
3.1. Study Description. After screening 1553 studies, a total of
31 articles on tulsi met the inclusion criteria. Four articles
were excluded due to being inaccessible and one article
reported two independent clinical studies, while one clinical
trial was reported in three separate articles. This left a total
of 24 independent clinical studies to be reviewed. A flow
chart of the systematic search and study selection protocol is
presented in Figure 1.
The reviewed studies involved a total of 1111 participants
with ages ranging from 10 to 80 years old with eight clinical
trials limiting participants to ≥40 years old [38, 61, 66, 68–
70, 72, 75]. Only three clinical trials included 100 or more
participants [65, 66, 82]. The study durations ranged from
2 to 13 weeks and tulsi dosage and frequency varied from
300mg to 3000mg given as 1–3 times per day as tulsi leaf
aqueous extract; 300mg–1000mg once or twice per day as
tulsi leaf ethanolic extract; 6 g to 14 g per day as the tulsi
whole plant aqueous extract; and 10 g fresh tulsi leaf aqueous
extract administered as once or four equal doses daily, and as
tincture solution 30 drops a day were administered as three
equal doses daily.
From the 24 studies identified only eight included a
placebo [66, 68, 70, 75–77, 81, 82]. Five of the included trials
adopted a two-arm parallel design [62, 63, 65, 67, 80], while
four used a cross-over design with one being described in
three different papers that reported on two different sets of
outcomes [70, 75, 77].
Included studies were classified according to three major
clinical domains: metabolic related disorders; immunity; and
neurocognitive function (Tables 1, 2, and 3). Only two studies
described the type of tulsi (Krishna) used while all other
papers referred to tulsi as Ocimum sanctum [71, 72] not
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Studies identied through
database search
Searched full text articles
Clinical studies identied
(i) Reviews
(ii) Nonclinical studies
(iii) Nonhuman
(iv) No outcome
(v) Topical application
(vi) Polyherbal formulation
Duplicated records removed
Studies identied through other sources such
as books, thesis, and Indian journals
Total studies identied
Clinical studies included in
Inaccessible records removed
Identical records removed
(n = 3)
(n = 4)
(n = 24)
systematic review
(n = 1552)
(n = 156)
(n = 538)
Records excluded
(n = 983)
(n = 31)
(n = 1014)
(n = 1396)
Figure 1: Flow chart of systematic search and study selection protocol.
distinguishing between cultivars. Four studies reported on
the use of tulsi alone and alongwith food, hypoglycemic drug,
curry or Neem [63, 67, 69, 76]. Most studies looked at clinical
populations with specific acute or chronic illnesses, such as
viral infection, psychological stress, diabetes, or metabolic
syndrome, with only three studies reporting on the effects of
tulsi in healthy human participants [74, 76, 81].
3.2. Effectiveness and Safety Evaluation. The most common
outcome measurements were related to blood glucose levels
(8 studies), lipid profile (6 studies), blood pressure (6 studies),
immune response (6 studies), and neurocognitive changes (4
studies). Other outcomes included mood (3 studies), fatigue
(2 studies), uric acid levels (2 studies), diabetes secondary
symptoms (1 study), and sleep (1 study). Fifteen of the 24
included studies reported no adverse events and eight studies
did not describe or refer to any adverse events. Only one study
that used tulsi leaf extract as 250mg capsule taken before
meals twice daily in 16 obese adults reported the occurrence
of occasional nausea.
3.3. Quality Assessment. The studies were classified as either
Randomized Clinical Trial Placebo Controlled (RCT-PC 6),
Randomized Clinical Trials with no placebo (RCT 7), or
Clinical Trials where no information on randomization or
control was available (CT 6). Only three out of 24 studies,
two of which examined neurocognitive effects [81, 82] and
one reported on immunity as well as cardiovascular changes
[74, 77], were rated as high quality with Jadad scores of 4-
5 points, with the remaining studies varying in quality with
Jadad scores ranging from 0 to 3 points. The score for each
included study is presented in Tables 1–3.
3.4. Metabolic Disorders. Seventeen clinical trials reported
on metabolic conditions with ten studies reporting on type
2 diabetes or metabolic syndrome with measures of blood
glucose, lipids, and blood pressure, yet only one study
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reported on the clinical symptoms associated with type 2
diabetes such as polydipsia, polyphagia, polyuria, sweating,
fatigue, burning feet, itching, and headache [69]. In addition
one study reported on obesity [62] and two studies on uric
acid changes in participants with gouty arthritis [38, 65].
Six of the identified trials on metabolic conditions were
randomized clinical trials with placebo controls [66, 68, 70,
74, 75]. In addition, eight studies were of 2–5 weeks duration
[38, 63, 64, 70, 73–75], three were of 6–8 weeks [61, 62, 68],
and six were of 12-13 weeks [65–67, 69, 71, 72]. When the
duration of the tulsi intervention was increased from 4-5
weeks [38, 70] to 12-13 weeks there was a more dramatic
reduction in fasting blood glucose (FBG) and postprandial
glucose (PPG) compared to controls [66, 67]. In particular,
HbA1c (35.8%) significantly decreased when tulsi was added
as adjunct therapy to hypoglycemic medication compared to
drug medication alone [67].
The earliest clinical trial conducted in 1964 with 10
patients with type 2 diabetes reported that over a period of
12 weeks, a 14 g decoction of whole Krishna tulsi plant led
to a gradual improvement in fasting blood glucose in 9 out
of 10 patients [71]. Three decades later, the first randomized
placebo-controlled clinical trial reported daily ingestion of
2.5 g of tulsi leaves led to significant improvements of FBG,
PPG, and urine glucose in type 2 diabetes patients after 4
weeks [70]. In addition, Rai et al. reported that 4weeks of sup-
plementation with tulsi powder significantly lowered blood
glucose and glycated proteins, reduced uric acid levels, and
improved lipid profiles in participants with type 2 diabetes
[38]. In comparable trials with longer durations, FBG and
PPG improved by 1.2–2.2 and 1.5–6.0 folds, respectively, while
HbA1c improved 1.5 and 3.2 fold after 12-13 weeks [66, 67].
Similarly, lipid profile was improved significantly inMetS and
diabetes participants in three clinical trials [38, 66, 68] with
a separate clinical trial reporting significant improvement in
lipid profile in obese participants [62] and a further study
reporting improved lipid levels in healthy subjects [74].
A further 12-week study of type 2 diabetes patients
reported greater improvement in both blood glucose and
HbAc1 levels when 300mg of tulsi leaf extract was adminis-
tered along with the antidiabetic drug glibenclamide, com-
pared to drug treatment alone [67]. Similarly, a controlled
trial of patients with diabetes found that consumption of 2 g
of tulsi powdered leaves, either alone or combined with curry
leaves, led to significant improvement in blood sugars after
two weeks [63]. In a further 12-week randomized trial in
diabetic patients, 2 g of tulsi leaf extract alone or combined
with neem leaf extract produced marked reduction in dia-
betic symptomswith greatest effect noted for the combination
[69].
Six trials reported on the effect of tulsi on individual
features of metabolic syndrome [62, 72–75]. Two studies
reported significant improvement of blood pressure in hyper-
tensive participants given 30mL of fresh tulsi leaf juice once
daily or 30mL twice a day for 10 and 12 days, respectively
[75], with a further study reporting normalisation of blood
pressure in hypotensive adult females [73]. Yet another study
reported improvement in serum lipids with no difference in
blood pressure in healthy adults administered 300mg per
day of tulsi leaf ethanolic extract for 4 weeks [74]. A further
study reported improved lipid profiles in older adults (60–80
years) with psychosomatic symptoms after administration
of 3 g of whole plant tulsi extract twice daily for 12 weeks
[72]. A more recent study also reported improvement in lipid
profiles, as well as BMI of obese participants administered
250mg capsules of tulsi leaf extract twice daily for 8 weeks
[62].
3.5. Immunomodulation and Inflammation. Enhanced im-
mune responsewas reported in five clinical studies [76–80]. A
small randomized double-blind, and placebo-controlled trial
found increased immune response with increased Natural
Killer (NK) and T-helper cells in healthy adult participants
compared to placebo volunteers after 4 weeks of 300mg
or ethanolic tulsi leaf extract daily taken before food [77].
Another 2-week controlled randomized study in which
young adult volunteers were provided with nutrition bars
fortified with 1 g of ethanolic tulsi leaf extract found that
compared to control participants, the intervention group
had significantly improved VO2 max, less fatigue, reduced
Creatine Kinase, and improved immune response to viral
infection as indicated by reduced load of human herpesvirus
6 in saliva [76].
Two clinical trials studied the effect of daily adminis-
tration of 10 g of an aqueous extract of fresh tulsi leaves in
patients with acute viral infections, with a study on patients
with acute viral encephalitis reporting increased survival
after 4 weeks in the tulsi group compared to a group given
dexamethasone and a study on viral hepatitis reporting
symptomatic improvement after 2 weeks [79, 80]. A further
study of asthmatic patients found that 500mg of dried tulsi
leaves taken three times daily improved vital capacity and
provided relief of asthmatic symptoms within 3 days [78].
3.6. Neurocognitive Effect. The four studies that reported on
neurocognitive effects all showed significant improvements
in mood and/or cognitive function regardless of age, gen-
der, formulation, dose, or quality of the study [72, 81–83].
Cognition function was assessed in a randomized, placebo-
controlled, clinical trial that demonstrated an improvement
in cognitive flexibility, short-term memory, and attention in
40 healthy young adults (17–30 years) following treatment
with 300mg daily tulsi for 4 weeks [81]. However, the
cognitive effects of tulsi were only significant after the first
two weeks compared to the placebo, with no significant
difference found in stress levels. This is in contrast to three
clinical studies that reported significant reduction in anxiety
and stress levels with higher doses of tulsi given over a longer
time period [72, 82, 83]. The positive effect of tulsi on mood
was demonstrated in three studies, with two studies reporting
reductions of 31.6%–39% in overall stress-related symptoms
in patients with psychosomatic problems compared to a
control group [82, 83].
4. Discussion
Despite a long history of traditional use and widespread
availability, relatively few human intervention studies have
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been conducted on the effectiveness of tulsi for clinical con-
ditions and this is the first comprehensive literature review of
published human research on the ingestion of tulsi as a single
herbal intervention. The studies identified in this review
could be classified according to three main clinical domains
including metabolic disorders (15 studies), neurocognitive or
mood conditions (4 studies), and immunity and infections
(5 studies), which are all extremely relevant to the growing
world-wide epidemic of lifestyle-related chronic disease. The
finding that the reviewed studies reported favourable clinical
effects across these domains suggests that tulsi may indeed be
an effective adaptogen that has a role in helping to address the
psychological, physiological, immunological, and metabolic
stresses of modern living.
It is interesting that tulsi has important clinical effects
across diverse therapeutic domains, all of which may have
inflammation as an underlying factor.The anti-inflammatory
effects of tulsi have been previously documented in many in
vitro and in vivo studies [43, 85–88], and it is likely that tulsi
has multiple bioactive secondary metabolites that act alone
or synergistically to inhibit inflammatory pathways. There
is also evidence to suggest that tulsi may be useful as an
adjunct to pharmacotherapy and nutrition in the treatment of
metabolic disorders thereby reducing the need for high doses
of drugs, which may have adverse effects. The clinical effects
demonstrated in the reviewed studies suggest tulsi may have
an important role in addressing other inflammatory disorders
and that the Ayurvedic tradition of consuming tulsi on a daily
basis may be an effective lifestyle measure to address many
modern chronic diseases.
The most commonly used part of the tulsi plant is the
leaf (dried or fresh), which is known to contain several
bioactive compounds including eugenol, ursolic acid, 𝛽-
caryophyllene, linalool, and 1,8-cineole [89–91]. Eugenol has
been found to be the major bioactive metabolite common to
all three tulsi varieties with varying amounts in each cultivar
[92, 93] and it has recently been suggested to act via dual
cellular mechanisms to lower blood glucose levels. These
include competitively preventing the binding of glucose to
serum albumin and inhibiting the conversion of complex
carbohydrate to glucose [93]. However, while eugenol has
been shown to be bioactive, the phytochemical composition
of tulsi is very complex and varies depending on different
conditions [94–97] and there are many other potential
active secondarymetabolites such as other phenylpropanoids
(methyl eugenol, rosmarinic acid), monoterpenes (ocimene),
and sesquiterpenes (germacrene) that could alone or syner-
gistically produce therapeutic benefits [98].
All reviewed studies reported favourable clinical effects
with minimal or no side effects irrespective of dose, formu-
lation, or the age or gender of participants, with only one
clinical trial reporting transient mild nausea [62]. As the
longest study was only 13 weeks, the failure to report any
adverse effects does not preclude the presence of any long
term side effects; however, the long traditional history of
regular tulsi use suggests any serious long term effects are
unlikely and that daily ingestion of tulsi is safe. Furthermore,
the results of this review are consistentwith previous evidence
for the clinical efficacy and safety of tulsi, which includes
multiple in vitro and in vivo studies andmany human clinical
trials in addition to traditional use.
4.1. Limitations and Scope. This review, which comprehen-
sively reviewed all human clinical trials published in English
language on ingestion of tulsi as a single herb, has many limi-
tations. While the review included 24 studies and minimized
bias by using a systematic and independent search strategy
without limiting publication year or study design, we cannot
be certain that all studies were located; this is especially due
to the fact that almost all studies were conducted in India and
published in local journals, some of which are very difficult
to access or search. There may also be unpublished studies
that report negative outcomes [99]. Furthermore, while the
reviewed studies were consistent in reporting positive effects
of tulsi in humans, only 7 out of 24 can be considered
high quality studies with all but three failing to include a
double-blind strategy. Tulsi’s therapeutic effects may have
therefore been overestimated and while the efficacy of tulsi
was reported across a wide range of formulations and doses,
many studies also failed to provide details of the cultivar,
dosage form, or specific dosage or quality control measures
of the tulsi used.
This review suggests that tulsi is an example of the
Ayurvedic holistic lifestyle approach to health and appears
to provide a vast array of health benefits that offers solutions
to many modern day health problems. While the reviewed
studies could be classified into three major therapeutic
domains, there is insufficient evidence for any specific tulsi
formulation to assist in any one condition. More rigorous
studies with larger sample sizes and longer durations and
standardised formulations are therefore needed before spe-
cific recommendations can be made for the treatment of
any specific disease. This review further highlights the need
to investigate and determine unique signature compounds
specific to each of the three tulsi varieties, to not only identify
the bioactivemetabolites thatmay synergistically interact, but
also shed light on the underlying mechanism of action on
metabolic and inflammatory pathways.
5. Conclusion
Despite the lack of large-scale or long term clinical trials
on the effect of tulsi in humans, the findings from 24
human studies published to date suggest that the tulsi is
a safe herbal intervention that may assist in normalising
glucose, blood pressure and lipid profiles, and dealing with
psychological and immunological stress. Furthermore, these
studies indicate the daily addition of tulsi to the diet and/or as
adjunct to drug therapy can potentially assist in prevention or
reduction of various health conditions and warrants further
clinical evaluation.
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